Project Grant R01HL168874
Award Date
7/1/24
Completion Date
5/31/28
Dollars Obligated
$635K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
The University of California, Davis (UC Davis) was awarded a $1,738,092 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The project aims to identify key molecular and cellular functional changes in heart failure with preserved ejection fraction (HFpEF) using a preclinical animal model, and investigate the impact of HFpEF heterogeneity on disease mechanisms and potential therapies. Informed by...
This $135,840 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a multi-scale computational and experimental platform to investigate the mechanisms of cardiac contractile dysfunction in common cardiomyopathies. The research aims to establish a framework for understanding how structural perturbations to the myosin motor protein affect its interaction with actin, and to develop small molecule...
The University of California, San Diego (UCSD) was awarded a Project Grant of $1,451,467 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The objective of this 4-year grant, which runs from July 1, 2024 to June 30, 2028, is to investigate the mechanisms by which juxta-cardiac field progenitors develop into the diverse cell types that comprise the mammalian heart. The research will employ a multidisciplinary, systems...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $125,568 to The Leland Stanford Junior University to explore the molecular mechanisms governing the import and regulation of NAD+ within the mitochondrial matrix. The research aims to elucidate how mitochondria maintain adequate NAD+ levels and how this process may become dysregulated in heart failure, a prominent global health...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to identify transcriptional regulators of endocardial-specific gene expression and understand how these regulate heart development, homeostasis, and regeneration. The award, totaling $540,856.00 and spanning from December 2024 to November 2028, will be conducted by the Regents of the University of California, San...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for treating inherited dilated cardiomyopathy (DCM). The $2,408,580 grant, awarded on July 16, 2024, supports research at The Leland Stanford Junior University (Stanford University) to explore the selectivity and mechanisms of this pathway in...
This $2,212,585 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of adenine metabolism in cardiac remodeling and its potential as a therapeutic target for treating ischemic heart injury. The multi-disciplinary research team will examine the mechanisms of adenine generation and transport, as well as the biochemical effects on NAD and pyrimidine biosynthesis,...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $393,750 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, Los Angeles (UCLA) to develop a population-based computational approach for predicting and preventing ventricular arrhythmias, a leading cause of sudden cardiac death. The research aims to: 1) Discover effective antiarrhythmic drug therapies by targeting dynamical parameters as...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,512 to the University of California, San Diego (UCSD) to investigate how the mechanical properties of cardiac tissue, specifically tissue elasticity and viscosity, modulate the signaling between macrophages and fibroblasts in the context of cardiac fibrosis. The research aims to develop an engineered cell culture system to...